Hepatocellular carcinoma, the most common form of primary liver cancer, is a disease of vigilance. Even when a tumor is successfully eliminated, the underlying cirrhotic liver that produced it remains fertile ground for new malignancies, and recurrence can appear either at the ablation site or anywhere else in the organ. International guidelines from the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Korean Liver Cancer Association therefore recommend serial imaging every three to six months after treatment, a schedule patients typically maintain indefinitely. Missing an early recurrence can mean the difference between another curative intervention and advanced, incurable disease.

The standard surveillance toolkit has long been a compromise. Computed tomography with intravenous contrast exposes patients to cumulative radiation and carries risks of contrast allergy and kidney injury, making it a suboptimal choice for patients who may need dozens of scans over a lifetime. Complete-protocol MRI with gadolinium-based contrast is widely considered the best imaging modality for detecting and characterizing hepatocellular carcinoma, but it is constrained by long scan times, high cost, limited scanner access, and the specialized expertise required to interpret dozens of image series. That bottleneck has motivated radiologists to ask a deceptively simple question: how much of the full scan is actually necessary?

The UCLA team, led by Pedram Keshavarz and senior authors Steven S. Raman and David S. K. Lu, tested an abbreviated MRI protocol built around just two sequences: the hepatobiliary phase of a gadoxetic acid-enhanced scan and a single-shot T2-weighted sequence. Gadoxetic acid is a liver-specific contrast agent, roughly half of which is excreted through the bile after injection. In the late hepatobiliary phase, typically captured fifteen to twenty minutes after administration, functioning hepatocytes take up the agent through organic anion transporting polypeptide transporters on their surface and appear bright. Most hepatocellular carcinomas lack these transporters, so tumors stand out as dark defects against the glowing liver, a contrast mechanism that makes the hepatobiliary phase exceptionally sensitive for cancer detection.

To evaluate the shortened protocol, the researchers assembled a retrospective cohort of 43 patients, mean age about 70 years and overwhelmingly male, who had undergone percutaneous microwave ablation for naive hepatocellular carcinoma at a tertiary care liver transplant center between January 2017 and December 2019. Nearly all had cirrhosis, most commonly from chronic hepatitis C or alcoholic liver disease. The cohort yielded 215 complete gadoxetic acid-enhanced surveillance MRI exams. Twenty-seven consecutive patients with recurrence contributed 48 positive and 86 negative exams, and 16 randomly selected patients without recurrence added another 81 negative exams, deliberately enriching the dataset with negative studies to approximate real-world screening conditions. Three board-certified abdominal radiologists, blinded to all clinical information, then independently reviewed the abbreviated versions of each exam, comparing them against the original full-protocol reports, which served as the reference standard.

The results were striking. On a per-patient basis, the abbreviated protocol achieved pooled sensitivity of 86.4 percent, specificity of 100 percent, and a negative predictive value of 88.1 percent for detecting recurrence of any type. Analyzed exam by exam, the numbers were 87.5 percent sensitivity, 97.6 percent specificity, and 93.3 percent negative predictive value, with an area under the receiver operating characteristic curve of 0.90. For recurrences confined to the ablation zone, per-patient sensitivity was 85.7 percent with perfect specificity, while for recurrences elsewhere in the liver the protocol detected 86.6 percent of cases, also with perfect specificity, though the negative predictive value for these distant recurrences dipped to 72.4 percent. Perhaps most impressive was the consistency between readers: inter-reader agreement was excellent, with a kappa of 0.91 per patient, comparable to the agreement reported for full-protocol interpretation of treated lesions.

The failures of the abbreviated scan were as informative as its successes. Across 645 readings, only three false positives occurred, attributable to motion artifact mimicking a nodule, a siderotic regenerative nodule, and a benign pseudolesion, all of which would likely be resolved by a confirmatory full MRI in clinical practice. False negatives were more numerous, eleven in total, and clustered around small recurrences measuring roughly 10 to 16 millimeters that showed arterial hyperenhancement on the complete scan but were invisible or only partially visible as defects on the hepatobiliary phase. A small minority of hepatocellular carcinomas, estimated at 5 to 10 percent, retain the transporter expression that makes them take up gadoxetic acid, the so-called green hepatocellular carcinomas, and these can evade detection on hepatobiliary-phase imaging alone.

The study builds on a growing body of evidence that abbreviated MRI works for primary screening of at-risk cirrhotic patients, where gadoxetate-enhanced abbreviated protocols have reported sensitivities in the low 80 percent range. What distinguishes the new work is its focus on secondary surveillance, the follow-up of patients already treated for hepatocellular carcinoma, a setting with far fewer published data. A Korean study by Jeon and colleagues previously found no significant difference between abbreviated and full-protocol MRI for detecting post-treatment recurrence, with per-patient sensitivity of 73.1 percent for the abbreviated approach, and the UCLA results, with higher sensitivity, reinforce the case that trimming the protocol does not meaningfully compromise cancer detection.

The clinical implications are considerable. A surveillance exam consisting of two sequences instead of the full multiphasic battery could shorten scanner time substantially, reduce per-exam cost, and expand access for the many patients who currently face months-long waits for liver MRI. Because a negative abbreviated scan reliably excludes recurrence, the authors argue, it could spare patients unnecessary comprehensive imaging, lowering both healthcare expenditure and patient burden. A positive abbreviated scan, meanwhile, would simply trigger a confirmatory complete MRI, meaning false positives carry less clinical harm than false negatives. The researchers also point to the horizon: deep learning reconstruction is already being used to denoise images and cut scan times further, and experimental synthetic contrast techniques have produced gadolinium-free contrast-enhanced MRI in as little as four minutes, compared with 28 minutes for standard protocols.

The authors are careful to note the caveats. The study was retrospective, the enriched proportion of recurrence-negative exams does not reflect a true clinical population, no formal cost or time savings were quantified, the abbreviated protocol omitted diffusion-weighted imaging, and exams spanned both 1.5 and 3 Tesla scanners. Larger prospective and multicenter trials will be needed before abbreviated protocols become standard practice. Still, for the hundreds of thousands of patients worldwide who live under the shadow of hepatocellular carcinoma recurrence, the message is hopeful: the future of surveillance may be shorter, safer, and just as sharp.

Subject of Research: Abbreviated hepatobiliary phase MRI for surveillance of hepatocellular carcinoma recurrence after microwave ablation

Article Title: Hepatobiliary phase abbreviated MRI for secondary surveillance after microwave ablation of HCC

Article References: Keshavarz, P., King, K. G., Depetris, J., Quirk, M., Kang, T. W., Sayre, J., Tong, M. J., McWilliams, J. P., Raman, S. S., & Lu, D. S. K. (2025). Hepatobiliary phase abbreviated MRI for secondary surveillance after microwave ablation of HCC. CVIR Oncology, 1(1), Article 6. https://doi.org/10.1007/s44343-025-00007-1

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00007-1

Keywords: hepatocellular carcinoma, abbreviated MRI, hepatobiliary phase, microwave ablation, secondary surveillance, gadoxetic acid, liver cancer recurrence, radiology, medical imaging, cirrhosis, negative predictive value, deep learning MRI

The tool designed to close that gap is surveillance, the repeated testing of asymptomatic people at risk of a disease so that it can be detected early. All major international professional bodies, including the European Association for the Study of the Liver, the American Association for the Study of Liver Disease and the Asian Pacific Association for the Study of the Liver, recommend that patients with cirrhosis and high-risk chronic hepatitis B undergo liver ultrasound with or without serum alpha-fetoprotein measurement every six months. The annual risk of developing hepatocellular carcinoma in chronic liver disease ranges from about 1 per cent in alcohol-related cirrhosis to 2 per cent in hepatitis B and 3 to 8 per cent in hepatitis C. But a comprehensive review published in The Lancet Regional Health – Europe reveals that the evidence underpinning this universal recommendation is far shakier than most clinicians and patients realise, and that the gap between what guidelines advise and what actually happens in clinics is enormous.

The mortality benefit of surveillance rests largely on a single randomised controlled trial conducted in China, which found that six-monthly ultrasound with or without alpha-fetoprotein reduced hepatitis B-related liver cancer mortality by 37 per cent. No subsequent randomised study has ever replicated the finding, and further trials are widely considered unfeasible or unethical. In one Australian feasibility study, 99.5 per cent of patients declined randomisation to a no-surveillance arm. In place of trial data, the field relies on cohort studies and modelling: a meta-analysis of 59 international studies involving 145,396 patients found that surveillance was associated with earlier-stage diagnosis, higher receipt of curative treatment and improved overall survival after adjustment for lead-time bias. Critics counter that a trial in largely non-cirrhotic hepatitis B carriers may not generalise to older, sicker cirrhotic populations facing competing causes of death, a concern underscored by Danish registry data showing that liver cancer contributes only modestly to mortality in alcohol-related cirrhosis.

The surveillance test itself is also under scrutiny. Ultrasound is operator-dependent, with a sensitivity of just 47 per cent for early disease, and performance deteriorates further in patients with obesity or advanced cirrhosis. Around 20 per cent of surveillance ultrasounds are judged inadequate to visualise the liver, a particularly troubling statistic as metabolic dysfunction-associated steatotic liver disease, or MASLD, surges across populations with rising adiposity. Computed tomography and magnetic resonance imaging can be substituted when visibility is poor, but no randomised evidence supports cross-sectional imaging for surveillance, and cost, radiation and cumulative gadolinium exposure limit enthusiasm. Meanwhile, the harms of surveillance, physical, financial and psychological, have never been systematically quantified at scale. One United States study found physical harms in 27 per cent of patients, and emerging work highlights anxiety, false positives and out-of-pocket costs as meaningful burdens whose weight likely varies with a patient’s baseline cancer risk.

Against this contested backdrop, actual uptake of surveillance is dismal. A recent meta-analysis of 49 studies covering more than 1.2 million patients found that while 54 per cent of eligible people received some surveillance, fewer than 10 per cent received the guideline-concordant biannual testing. Country-level figures expose the patchwork: biannual uptake is around 17 per cent in the United Kingdom, 8 per cent in France, 4 per cent in Norway and under 20 per cent in the United States, compared with roughly 80 per cent in Japan and 75 per cent in Taiwan. Barriers span three levels. Patients may lack awareness of their risk or face logistical and financial constraints; clinicians report limited knowledge, time pressure and scepticism about the guidelines; and health systems lack national programmes, registries and recall infrastructure to keep at-risk patients in the loop.

Europe’s institutional response has been strikingly ambivalent. Europe’s Beating Cancer Plan, launched in 2021 with 4 billion euros earmarked for cancer action, explicitly declines to support liver cancer surveillance, with the European Commission stating that screening elevated-risk people entails uncommon but serious harms and might not reduce mortality. The United States National Cancer Institute draws a similarly pessimistic conclusion from the same Chinese trial. Professional societies, meanwhile, continue to recommend surveillance, leaving patients and advocacy groups lobbying for care that many clinicians, awaiting formal national guidance, remain reluctant to organise. The authors of the review argue that this deadlock leaves cirrhotic and viral hepatitis patients in a state of flux, receiving variable care in a disease that disproportionately affects society’s most marginalised members.

The contrast with countries that have committed to national programmes is instructive. Japan, the first nation to implement organised liver cancer surveillance, built its system in the 1980s through close cooperation between the Japan Society of Hepatology, government ministries and frontline hospitals. Super-high-risk patients, such as those with viral cirrhosis, are scanned every three to four months with ultrasound plus three tumour markers, alpha-fetoprotein, AFP-L3 and PIVKA-II, with optional dynamic CT or Gd-EOB-MRI once or twice a year. Ultrasounds are frequently performed directly by hepatologists rather than radiologists, and an annual eradication campaign, nationwide hepatitis testing and electronic record alerts keep risk populations engaged. The results are unmatched: more than 80 per cent of high-risk individuals covered, 65 per cent of cancers diagnosed at early BCLC stage 0 or A, and a five-year survival of 43 per cent, more than double the European figure. Taiwan pairs a reimbursed surveillance programme with its hepatitis B vaccination success, while Egypt offers free lifelong four-monthly monitoring through 58 specialised units. Thailand has shown that risk scores and the GAAD biomarker panel can cut the surveillance-eligible population dramatically and cost-effectively.

Within Europe itself, national philosophies diverge sharply. Denmark restricts surveillance to viral hepatitis and PAGE-B high-risk patients, judging the evidence insufficient for alcohol-related or MASLD-related cirrhosis, where local registry data show an annual cancer incidence of just 0.7 per cent; it is now trialling surveillance for all cirrhosis patients in one region to generate better evidence. Spain operates a clinician-led, risk-stratified model with uptake approaching 80 per cent in specialised care, though only 47 per cent of national cases are detected through surveillance. The United Kingdom, despite running the world’s largest universal healthcare system, records some of the worst hepatobiliary cancer outcomes among wealthy nations, with under 20 per cent of patients receiving curative therapy and emergency presentation the most common route to diagnosis. A community pilot programme has referred 7,892 patients to hepatology, but no formal health-economic evaluation has yet been published, and the country still lacks a national cirrhosis registry.

The patient experience, often overlooked in policy debates, adds a further layer of urgency. A British Liver Trust survey of 135 people affected by primary liver cancer found surveillance frequently undermined by poor communication, inconsistent delivery and stigma. Patients reported not understanding what the scans were for, being forgotten by their liver teams, waiting more than six months for appointments and travelling over 20 miles for care. Many described feeling blamed for their disease, with assumptions about alcohol use shaping their engagement with services. The review’s authors argue that surveillance must be reframed as a patient-centred pathway, consistent, clearly communicated, stigma-aware and locally accessible, or it risks reinforcing the very inequalities it is meant to counter.

The path forward, the authors suggest, lies in three converging innovations. First, risk stratification: tools such as the aMAP score, FIB-4 index, the Toronto HCC risk index and elastography-based stiffness measures could concentrate resources on those most likely to benefit, an approach already trimming eligible populations in Thailand and Denmark. Second, novel biomarkers: the GALAD score has passed phase III validation, outperforming alpha-fetoprotein in detecting cancer up to 12 months before diagnosis, while methylated DNA panels such as mt-HBT and HelioLiver show comparable early-stage sensitivity, and patients consistently prefer blood tests to ultrasound. Third, abbreviated MRI, a faster, cheaper imaging protocol now being tested in multiple international trials, may serve populations poorly served by ultrasound, particularly those with MASLD. The authors’ key recommendations call for a large multinational risk-based trial, research into alternative modalities, free surveillance at the point of care, patient navigation programmes and coordinated advocacy by professional societies and patient groups toward the European Commission and National Cancer Institute. With MASLD projected to become the leading cause of liver cancer, often arising even without cirrhosis, the authors warn that Europe’s current deadlock is untenable: further observational studies will not convince sceptics, and only pragmatic, risk-based, well-funded programmes, on the model of Japan, Taiwan and Egypt, can translate four decades of partial evidence into falling mortality.

Subject of Research: Hepatocellular carcinoma surveillance practices, evidence and barriers in Europe and globally

Article Title: Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice

Article References: Qurashi, M., Buti, M., Lai-Hung Wong, G., Qureshi, H., Kudo, M., Tanwandee, T., Chen, C.-J., Abdelaziz, A. O., AbdAllah, M., Howell, J., Hebditch, V., Singal, A. G., Jepsen, P., & Sharma, R. (2026). Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice. The Lancet Regional Health – Europe, 70, Article 101852. https://doi.org/10.1016/j.lanepe.2026.101852

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101852

Keywords: hepatocellular carcinoma, liver cancer, surveillance, cirrhosis, ultrasound, alpha-fetoprotein, MASLD, hepatitis B, GALAD biomarker, abbreviated MRI, risk stratification, Europe